Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051397 | 0.78 | BMPR1B (0.50) | RIPK1HSD17B10SRD5A1BMPR1BBMPR1A | |
| SCHEMBL30404193 | 0.78 | BMPR1B (0.50) | RIPK1HSD17B10SRD5A1BMPR1BBMPR1A | |
| SCHEMBL25551352 | 0.74 | RIPK1 (0.48) | RIPK1HSD17B10MEN1BLMKMT2A | |
| SCHEMBL25551298 | 0.74 | RIPK1 (0.48) | RIPK1HSD17B10MEN1BLMKMT2A | |
| SCHEMBL726487 | 0.73 | RIPK1 (0.41) | RIPK1HSD17B10OPRK1 | |
| SCHEMBL8137963 | 0.73 | HSD17B10 (0.41) | RIPK1HSD17B10SRD5A1OPRK1BMPR1B | |
| SCHEMBL27858109 | 0.72 | RIPK1 (0.36) | RIPK1HSD17B10SRD5A1OPRK1 | |
| SCHEMBL26493269 | 0.72 | SRD5A1 (0.41) | RIPK1MEN1KMT2ASRD5A1 | |
| SCHEMBL17018038 | 0.71 | PDK1 (0.41) | RIPK1OPRK1 | |
| SCHEMBL34463406 | 0.71 | PDK1 (0.41) | RIPK1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD17B10 3631/4885MEN1 2334/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD17B10 3631/4885MEN1 2334/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD17B10 3631/4885MEN1 2334/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD17B10 3631/4885MEN1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.